# Exploring Sintilimab + Bevacizumab + Decitabine for Advanced pMMR/MSS Colorectal Cancer (After 2+ Prior Therapies）

Source: https://onco.cc/trials/nct07007767/  
OnCo record `nct07007767` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of sintilimab, bevacizumab and decitabine in colorectal cancer, run by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, not yet recruiting.

## Summary

Exploring Sintilimab + Bevacizumab + Decitabine for Advanced pMMR/MSS Colorectal Cancer (After 2+ Prior Therapies） is a phase 2, interventional study registered as NCT07007767 by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, with a registry enrolment figure of 32 participants, started 2025-06-15 and due to reach its primary completion in 2026-12-30. Interventions recorded: sintilimab; Bevacizumab Biosimilar; Decitabine. Conditions listed: Colorectal Cancer Metastatic. Primary outcome: Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as Assessed by Investigator Assessment. Colorectal eligibility wording from the registry: "Histologically confirmed colorectal adenocarcinoma;". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; colorectal-deep-dive
- Registry id: NCT07007767
- Phase: 2
- Setting: An Open-label, Single-arm, Exploratory Study of Sintilimab in Combination With Bevacizumab and Decitabine for the Treatment of Advanced pMMR/MSS Colorectal Cancer in Third-line or Later Settings
- Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Enrolled: 32

## Sources

- ClinicalTrials.gov NCT07007767: https://clinicaltrials.gov/study/NCT07007767

## Connected records

- cancers: [Colon cancer (adenocarcinoma of the colon)](https://onco.cc/cancers/colon-cancer/), [Rectal cancer](https://onco.cc/cancers/rectal-cancer/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/)
- drugs: [Bevacizumab](https://onco.cc/drugs/bevacizumab/), [Decitabine](https://onco.cc/drugs/decitabine/), [Sintilimab](https://onco.cc/drugs/sintilimab/)
- terms: [Colorectal cancer trials open today (registry snapshot)](https://onco.cc/terms/colorectal-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07007767.json